Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
Lung cancer is one of the leading causes of cancer-related death. Lung cancer mortality has decreased over the past decade, which is partly attributed to improved treatments. Curative surgery for patients with early-stage lung cancer is the standard of care, but not all surgical treatments have a go...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1011810/full |
| _version_ | 1827976999604322304 |
|---|---|
| author | Yurong Peng Zhuo Li Yucheng Fu Yue Pan Yue Zeng Junqi Liu Chaoyue Xiao Yingzhe Zhang Yahui Su Guoqing Li Fang Wu |
| author_facet | Yurong Peng Zhuo Li Yucheng Fu Yue Pan Yue Zeng Junqi Liu Chaoyue Xiao Yingzhe Zhang Yahui Su Guoqing Li Fang Wu |
| author_sort | Yurong Peng |
| collection | DOAJ |
| description | Lung cancer is one of the leading causes of cancer-related death. Lung cancer mortality has decreased over the past decade, which is partly attributed to improved treatments. Curative surgery for patients with early-stage lung cancer is the standard of care, but not all surgical treatments have a good prognosis. Adjuvant and neoadjuvant chemotherapy are used to improve the prognosis of patients with resectable lung cancer. Immunotherapy, an epoch-defining treatment, has improved curative effects, prognosis, and tolerability compared with traditional and ordinary cytotoxic chemotherapy, providing new hope for patients with non-small cell lung cancer (NSCLC). Immunotherapy-related clinical trials have reported encouraging clinical outcomes in their exploration of different types of perioperative immunotherapy, from neoadjuvant immune checkpoint inhibitor (ICI) monotherapy, neoadjuvant immune-combination therapy (chemoimmunotherapy, immunotherapy plus antiangiogenic therapy, immunotherapy plus radiotherapy, or concurrent chemoradiotherapy), adjuvant immunotherapy, and neoadjuvant combined adjuvant immunotherapy. Phase 3 studies such as IMpower 010 and CheckMate 816 reported survival benefits of perioperative immunotherapy for operable patients. This review summarizes up-to-date clinical studies and analyzes the efficiency and feasibility of different neoadjuvant therapies and biomarkers to identify optimal types of perioperative immunotherapy for NSCLC. |
| first_indexed | 2024-04-09T20:58:10Z |
| format | Article |
| id | doaj.art-05056e3275934b2d9fb5fcf5c5cff983 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T20:58:10Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-05056e3275934b2d9fb5fcf5c5cff9832023-03-29T13:58:14ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-01-011310.3389/fonc.2023.10118101011810Progress and perspectives of perioperative immunotherapy in non-small cell lung cancerYurong Peng0Zhuo Li1Yucheng Fu2Yue Pan3Yue Zeng4Junqi Liu5Chaoyue Xiao6Yingzhe Zhang7Yahui Su8Guoqing Li9Fang Wu10Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaThe Ophthalmologic Center of the Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaXiangYa School of Public Health, Central South University, Changsha, Hunan, ChinaXiangYa School of Public Health, Central South University, Changsha, Hunan, ChinaDepartment of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaLung cancer is one of the leading causes of cancer-related death. Lung cancer mortality has decreased over the past decade, which is partly attributed to improved treatments. Curative surgery for patients with early-stage lung cancer is the standard of care, but not all surgical treatments have a good prognosis. Adjuvant and neoadjuvant chemotherapy are used to improve the prognosis of patients with resectable lung cancer. Immunotherapy, an epoch-defining treatment, has improved curative effects, prognosis, and tolerability compared with traditional and ordinary cytotoxic chemotherapy, providing new hope for patients with non-small cell lung cancer (NSCLC). Immunotherapy-related clinical trials have reported encouraging clinical outcomes in their exploration of different types of perioperative immunotherapy, from neoadjuvant immune checkpoint inhibitor (ICI) monotherapy, neoadjuvant immune-combination therapy (chemoimmunotherapy, immunotherapy plus antiangiogenic therapy, immunotherapy plus radiotherapy, or concurrent chemoradiotherapy), adjuvant immunotherapy, and neoadjuvant combined adjuvant immunotherapy. Phase 3 studies such as IMpower 010 and CheckMate 816 reported survival benefits of perioperative immunotherapy for operable patients. This review summarizes up-to-date clinical studies and analyzes the efficiency and feasibility of different neoadjuvant therapies and biomarkers to identify optimal types of perioperative immunotherapy for NSCLC.https://www.frontiersin.org/articles/10.3389/fonc.2023.1011810/fullperioperative period perioperative immunotherapyneoadjuvant therapiesimmunotherapyneoadjuvant immune monotherapyadjuvant therapybiomarkers |
| spellingShingle | Yurong Peng Zhuo Li Yucheng Fu Yue Pan Yue Zeng Junqi Liu Chaoyue Xiao Yingzhe Zhang Yahui Su Guoqing Li Fang Wu Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer Frontiers in Oncology perioperative period perioperative immunotherapy neoadjuvant therapies immunotherapy neoadjuvant immune monotherapy adjuvant therapy biomarkers |
| title | Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer |
| title_full | Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer |
| title_fullStr | Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer |
| title_full_unstemmed | Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer |
| title_short | Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer |
| title_sort | progress and perspectives of perioperative immunotherapy in non small cell lung cancer |
| topic | perioperative period perioperative immunotherapy neoadjuvant therapies immunotherapy neoadjuvant immune monotherapy adjuvant therapy biomarkers |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1011810/full |
| work_keys_str_mv | AT yurongpeng progressandperspectivesofperioperativeimmunotherapyinnonsmallcelllungcancer AT zhuoli progressandperspectivesofperioperativeimmunotherapyinnonsmallcelllungcancer AT yuchengfu progressandperspectivesofperioperativeimmunotherapyinnonsmallcelllungcancer AT yuepan progressandperspectivesofperioperativeimmunotherapyinnonsmallcelllungcancer AT yuezeng progressandperspectivesofperioperativeimmunotherapyinnonsmallcelllungcancer AT junqiliu progressandperspectivesofperioperativeimmunotherapyinnonsmallcelllungcancer AT chaoyuexiao progressandperspectivesofperioperativeimmunotherapyinnonsmallcelllungcancer AT yingzhezhang progressandperspectivesofperioperativeimmunotherapyinnonsmallcelllungcancer AT yahuisu progressandperspectivesofperioperativeimmunotherapyinnonsmallcelllungcancer AT guoqingli progressandperspectivesofperioperativeimmunotherapyinnonsmallcelllungcancer AT fangwu progressandperspectivesofperioperativeimmunotherapyinnonsmallcelllungcancer |